Showing 391-400 of 2403 results for "".
- U.K Survey Reveals Eczema Treatment Knowledge Gaphttps://practicaldermatology.com/news/survey-reveals-eczema-treatment-knowledge-gap/2458049/Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 70 percent of patients, according to research from
- Derms Urged to Step Up Role in Antibiotic Stewardshiphttps://practicaldermatology.com/news/derms-urged-to-step-up-role-in-antibiotic-stewardship/2458126/Dermatologists can and should play a larger role in antibiotic stewardship, according to researchers out of Perelman School of Medicine at the University of Pennsylvania in Philadelphia. Data from the CDC shows the average dermatology provider wrote 669 antibiotic prescriptions in 2014, t
- Foamix Announces Additional Phase 3 Trial for FMX101 in Moderate to Severe Acnehttps://practicaldermatology.com/news/foamix-announces-additional-phase-3-trial-for-fmx101-in-moderate-to-severe-acne/2458203/Foamix Pharmaceuticals is launching an additional Phase 3 trial for FMX101 in moderate to severe acne, a topical minocycline treatment. If the results are positive, this new Phase 3 trial is expected to form the basis for a New Drug Application (NDA) which the company plans to submit in t
- New Biomarker May Help Guide Metastatic Melanoma Treatment Decisionshttps://practicaldermatology.com/news/new-biomarker-may-guide-metastatic-melanoma-treatment-decisions/2458253/Measuring levels of Bim—a protein made by cancer-fighting T cells—via a simple blood draw can help doctors predict which metastatic melanoma patients would benefit from anti-PD-1 checkpoint blockade. Such personalized medicine can help eliminate some of the trial and error ass
- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t
- Cloudy With a Chance of Wrinkles: Most Americans Fail to Protect Skin From Pollutionhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-most-americans-fail-to-protect-skin-from-pollution/2458275/Most Americans don’t protect their skin from pollutants even though they are aware of the harm that pollution and other environmental stressors can cause to skin, according to a new survey by H2O+ Beauty. Just 33 percent of people purchase
- Study: Anxiety, Depression May Travel with Hyperhidrosishttps://practicaldermatology.com/news/anxiety-depression-may-travel-with-hyperhidrosis/2458367/Individuals with hyperhidrosis are more likely to be anxious or depressed than their colleagues who don’t sweat excessively, new research suggests. Specifically, the prevalence of anxiety and depression was 21.3 percent and 27.2 percent in patients with hyperhidrosis, resp
- 23andMe Data Helps ID BCC Risk Geneshttps://practicaldermatology.com/news/23andme-data-helps-id-bcc-risk-genes/2458459/New research out of 23andMe and Stanford University School of Medicine pinpoints 31 genetic associations for basal cell carcinoma (BCC), 14 of which are all new. Taken together, these associations are estimated to explain almost 11 percent of the genetic risk for BCC, according to t
- Study: 98% of Head Lice in at Least 42 States Now Resistant to Common OTC Treatmentshttps://practicaldermatology.com/news/98-of-head-lice-in-at-least-42-states-now-resistant-to-common-otc-treatments/2458480/Fully 98 percent of head lice in at least 42 states are resistant to various over-the-counter pyrethrins and pyrethroids including permethrin, which is the active ingredient in popular treatment formulations for pediculosis (Nix® (permethrin 1%), according to a study in t
- Indoor Tanning Rates Among Minors in NJ Stays Same Despite 2013 Banhttps://practicaldermatology.com/news/indoor-tanning-rates-among-minors-in-nj-stays-same-despite-2013-ban/2458494/Indoor tanning rates among children under age 17 in New Jersey didn’t budge after a ban enacted in 2013, and rates increased among male high school students in the Garden State from 2012 to 2014, according to a study in the Journal